Luvagrobart Biosimilar - Research Grade

Human

NGF

>1mg/ml

IgG1 - kappa

CHO Cells

Tanezumab Biosimilar - Research Grade (ICH5102), Fasinumab Biosimilar - Research Grade (ICH5152), Fulranumab Biosimilar - Research Grade (ICH5157), Bedinvetmab Biosimilar - Research Grade (ICH5380), Izenivetmab Biosimilar - Research Grade (ICH5615), Ranevetmab Biosimilar - Research Grade (ICH5805)

https://www.imgt.org/mAb-DB/

ICH3002

P01138

Blue ice

This product (cat. ICH5665) is an unconjugated, non-therapeutic recombinant analog of the anti-NGF antibody Luvagrobart, supplied for research use only. It is a full-length human IgG1/kappa monoclonal built around neutralization of human beta-nerve growth factor (NGF; UniProt P01138), the same target addressed by the anti-NGF therapeutic class (e.g., tanezumab, fasinumab, fulranumab). It is not the clinical drug and is not intended for human or veterinary use. The analog is useful for in-vitro and preclinical research where a defined, well-characterized anti-NGF binder is needed: as a positive control or benchmark reference antibody, a ligand-neutralization tool, a capture or detection reagent in binding assays, and a scaffold for ADCC/effector-function or antibody-development workflows. It is offered at research grade with low endotoxin (typically less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg), and available in bulk milligram-to-gram quantities to support assay development, screening cascades, and scale-up. Because it is a biosimilar analog rather than the originator, it enables reproducible, cost-effective experimentation without regulatory or supply constraints of clinical material. Nerve growth factor (NGF; gene NGF/NGFB, UniProt P01138) is the prototypical neurotrophin, secreted as a proNGF precursor and processed to mature beta-NGF, which acts as a non-covalent homodimer. It signals through two receptors: the high-affinity receptor tyrosine kinase TrkA (NTRK1), which drives neuronal survival, differentiation, and axonal growth, and the low-affinity p75 neurotrophin receptor (NGFR). During development NGF is required for survival of sympathetic and sensory neurons; in adults it principally modulates nociceptor sensitivity and inflammatory pain signaling on TrkA-positive peripheral sensory fibers and mast cells. Elevated NGF is associated with inflammatory and chronic pain states, which is why NGF neutralization is an established analgesic strategy. Loss-of-function NGF mutations cause hereditary sensory and autonomic neuropathy type 5 (HSAN5), marked by impaired pain and temperature perception.

Beta-NGF, Beta-nerve growth factor, NGFB

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks